Search Results 6711-6720 of 25095 for oral
... Oral and throat cancer, Adenocarcinoma, Laryngeal cancer, Carotid body tumor, Tongue base cancer, Mouth tumor, Salivary gland cancer, Parotid cancer ...
No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors.
Inadequate response to an adequate course of appropriate oral antibiotics for treatment of HS in the last 1 year, as per investigator discretion. This is ...
Research at Mayo Clinic in diabetic nephropathy includes developing new diagnostic and treatment tools, such as oral medicines that may help stop or delay ...
Previous exposure to carisbamate or sensitivity/allergy to components of the oral suspension. Note: Other protocol defined Inclusion/Exclusion Criteria may ...
Adequate oral intake. PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified. Chemotherapy: Prior adjuvant chemotherapy allowed; No concurrent chemotherapy.
Patients with any condition that may impair the ability to absorb oral medications/investigational product including: Prior surgical procedures affecting ...
Immunosuppressive or immunomodulating treatment, including chronic oral or IV steroids, must be discontinued at least 4 weeks prior to screening. History of ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.